A minimally invasive procedure in which a sample is taken from a tumor or suspicious lesion using a thin needle, usually under ultrasound or CT guidance. It is used for assessment of tumors of the breast, lymph nodes, thyroid gland, lungs, and other organs.

Collection of a larger tissue sample using a special needle, allowing more detailed pathological analysis and more precise determination of the tumor type, aggressiveness, and treatment sensitivity.

Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are used for detection, localization, and assessment of tumor spread. These methods are also used to monitor the effect of treatment and identify possible new changes.

Processing and analysis of collected samples in cooperation with reference laboratories, in order to precisely determine the type of malignant disease and its characteristics.

Additional tests that detect specific tumor markers and receptors, important for selection of targeted or hormonal therapy.

Testing for genetic changes and mutations associated with specific types of cancer in order to select targeted therapy and provide personalized treatment.

Systemic treatment with cytotoxic drugs, adapted according to the type and stage of the malignant disease. Treatment is planned individually and may be administered as a standalone therapy, before surgery, after surgery, or in combination with other oncological methods.

The most common form of administration, in which medications are given through intravenous access. It is used in different types of solid tumors and hematological diseases.

Administration of therapy directly into the cerebrospinal fluid in patients with involvement or risk of involvement of the central nervous system. The department uses medications such as methotrexate and trastuzumab according to clinical indication.

Localized administration of therapy into the pleural cavity in patients with malignant pleural effusions or tumor changes of the pleura. Cisplatin and taxanes are most commonly used.

Administration of cytotoxic drugs directly into the abdominal cavity in patients with selected tumors and peritoneal metastases. Depending on the indication, oxaliplatin, cisplatin, and taxanes may be used.

Local treatment for bladder tumors, in which the medication is administered directly into the bladder. Gemcitabine is most commonly used.

Treatment aimed at reducing the side effects of chemotherapy, including therapy against nausea, pain, infections, anemia, and immune-related disturbances.

Treatment selection is based on the patient’s clinical condition, histopathological findings, genetic analyses, and individual characteristics, with the aim of achieving the best possible outcome and minimizing side effects.